Early events in ovarian epithelial carcinogenesis: Progress and problems in experimental approaches

International Journal of Gynecological Cancer

Volumn 12, Issue 6, 2002, Pages 691-703

  Auersperg, Nelly ^a   Ota, T ^a   Mitchell, G W E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Epithelial ovarian carcinoma; Experimental models; Ovarian carcinogenesis; Ovarian surface epithelium

Indexed keywords

CANCER DIAGNOSIS; CANCER SUSCEPTIBILITY; CARCINOGENESIS; EARLY DIAGNOSIS; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW;

ANIMALS; CARCINOMA; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; RESEARCH DESIGN;

EID: 0036855198     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2002.01152.x     Document Type: Review

References (146)

1. Wong AST, Auersperg N. Normal ovarian surface epithelium. Cancer Treat Res 2002;107:161-83.
2. Herbst AL. The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. Am J Obstet Gynecol 1994;170:1099-105.
3. Markman M. The role of CA-125 in the management of ovarian cancer. Oncologist 1997;2:6-9.
4. Young RH, Clement PB, Scully RE. The ovary. In: Stemberg SS, ed. Diagnostic Surgical Pathology. New York: Raven Press, 1989;1655-734.
5. Van Niekerk CC, Ramaekers FCS, Hanselaar AGJM, Aldeweireldt J, Poels LG. Changes in expression of differentiation markers between normal ovarian cells and derived tumors. Am J Pathol 1993;142:157-77.
6. Yang DH, Smith ER, Cohen C et al. Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity. Cancer 2002;94:2380-92.
7. Auersperg N, Wong AST, Choi KC, Kang SK, Leung PCK. Ovarian surface epithelium: Biology, endocrinology, and pathology. Endocrin Rev 2001;22:255-88.
8. Edmondson RJ, Monaghan JM. The epidemiology of ovarian cancer. Int J Gynecol Cancer 2001;11:423-9.
9. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC. The biology of ovarian cancer. Semin Oncol 1998;25:281-304.
10. Fathalla MF. Incessant ovulation - A factor in ovarian neoplasia? Lancet 1971;2:163.
11. Narod SA, Boyd J. Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. Curr Opin Obstet Gynecol 2002;14:19-26.
12. Auersperg N, Maines-Bandiera SL, Dyck HG, Kruk PA. Characterization of cultured human ovarian surface epithelial cells: Phenotypic plasticity and premalignant changes. Lab Invest 1994;71:510-8.
13. Dyck HG, Hamilton TC, Godwin AK, Lynch HT, Maines-Bandiera S, Auersperg N. Autonomy of the epithelial phenotype in human ovarian surface epithelium: Changes with neoplastic progression and with a family history of ovarian cancer. Int J Cancer 1996;69:429-36.
14. Sundfeldt K, Piontkewitz Y, Ivarsson K et al. E-cadherin expression in human epithelial ovarian cancer and the normal ovary. Int J Cancer 1997;74:275-80.
15. Kantak SS, Kramer RH. E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells. J Biol Chem 1998;273:16953-61.
16. Makrigiannakis A, Coukos G, Christofidou-Solomidou M et al. N-cadherin-mediated human granulosa cell adhesion prevents apoptosis: A role in follicular atresia and luteolysis? Am J Pathol 1999;154:1391-406.
17. Peluso JJ, Pappalardo A, Hess SA. Effect of disrupting cell contact on the nuclear accumulation of beta-catenin and subsequent apoptosis of rat ovarian surface epithelial cells in vitro. Endocrine 2000;12:295-302.
18. Huntsman D, Resau JH, Klineberg E, Auersperg N. Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy. Am J Pathol 1999;155:343-8
19. Kruk PA, Auersperg N. Human ovarian surface epithelial cells are capable of physically restructuring extracellular matrix. Am J Obstet Gynecol 1992;167:1437-43.
20. Kruk PA, Uitto VJ, Firth JD, Dedhar S, Auersperg N. Reciprocal interactions between human ovarian surface epithelial cells and adjacent extracellular matrix. Exp Cell Res 1994;215:97-108.
21. Murdoch WJ, Mcdonnel AC. Roles of the ovarian surface epithelium in ovulation and carcinogenesis. Reproduction 2002;123:743-50.
22. Kacinski BM, Carter D, Mittal K et al. Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1. Am J Pathol 1990;137:135-47.
23. Bast Jr. RC, Boyer CM, Jacobs I et al. Cell growth regulation in epithelial ovarian cancer. [Review] Cancer 1993; 71:1597-1601
24. Wong AST, Pelech SL, Woo MMM et al. Coexpression of hepatocyte growth factor-Met: An early step in ovarian carcinogenesis? Oncogene 2001;20:1318-28
25. Auersperg N, Siemens CH, Myrdal SE. Human ovarian surface epithelium in primary culture. In Vitro 1984;20:743-55.
26. Siemens CH, Auersperg N. Serial propagation of human ovarian surface epithelium in tissue culture. J Cell Physiol 1988;134:347-56.
27. McNeil L, Hobson S, Nipper V, Rodland KD. Functional calcium-sensing receptor expression in ovarian surface epithelial cells. Am J Obstet Gynecol 1998;178:305-13.
28. Kruk PA, Maines-Bandiera SL, Auersperg N. A simplified method to culture human ovarian surface epithelium. Lab Invest 1990;63:132-6.
29. Auersperg N, Maines-Bandiera SL. Culture and Characterization of human ovarian surface epithelium. In: Bartlett JMS, ed. Ovarian Cancer Methods & Protocols. Totowa, NJ: Human Press, 2000;39:169-74.
30. Osterholzer HO, Johnson JH, Nicosia SV. An autoradiographic study of rabbit ovarian surface epithelium before and after ovulation. Biol Reprod 1985;33:729-38.
31. Rodriguez GC, Berchuck A, Whitaker RS et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II Relationship between receptor expression and response to epidermal growth factor. Am J Obstet and Gynecol 1991;164:745-50.
32. Tsao SW, Mok SC, Fey EG et al. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res 1995;218:499-507.
33. Maines-Bandiera SL, Kruk PA, Auersperg N. Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. Am J Obstet Gynecol 1992;167:729-35.
34. Simmons DT. SV40 large T antigen functions in DNA replication and transformation. Adv Virus Res 2000;55:75-134.
35. Hu YL, Tee MK, Goetzl EJ et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 2001;93:762-8.
36. Tanyi JL, Lapushin R, Eder A et al. Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells. Gynecol Oncol 2002;85:451-8.
37. Manzano RG, Montuenga LM, Dayton M et al. CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene 2002;21:4435-47.
38. Auersperg N, Maines-Bandiera SL, Salamanca CM, Tam WTK, Godwin A. Induction of premalignant changes in cultured human ovarian surface epithelium (OSE). J Soc Gynecol Investig 2002;9:269A (Abstract).
39. Boyd J, Rubin SC. Hereditary ovarian cancer: Molecular genetics and clinical implications. Gynecol Oncol 1997;64:196-206.
40. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-89.
41. Frank TS, Critchfield GC. Identifying and managing hereditary risk of breast and ovarian cancer. Clin Perinatol 2001;28:395-406.
42. Thopmson D, Easton DF. Variation in cancer risks by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410-9.
43. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-82.
44. Fan S, Wang JA, Yuan R et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999;284:1354-6.
45. Zheng L, Annab LA, Afsahri CA, Lee WH, Boyer TG. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci U S A 2001;98:9587-92.
46. Favy DA, Rio P, Maurizis JC, Hizel C, Bignon YJ, Bernard-Gallon DJ. Prolactin-dependent up-regulation of BRCA1 expression in human breast cancer cell lines. Biochem Biophy Res Commun 1999;258:284-91.
47. Rebbeck TR, Kantoff PW, Krithivas K et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 1999;64:1371-7.
48. Levine DA, Boyd J. The androgen receptor and genetic susceptibility to ovarian cancer: Results from a case series. Cancer Res 2001;61:908-11.
49. Menin C, Banna GL, De Salvo G et al. Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer. Cancer Lett 2001;168:31-6.
50. Szabo CL, van Eijk R, Schreiber M et al. Androgen receptor CAG repeat length and BRCA1 associated breast cancer risk: Size does matter. Proceedings of the Genetic Modifiers of Cancer Susceptibility: Lessons from Human Population Studies and Mouse Models. Nevada: American Association for Cancer Research, 2001:31.
51. Lu KH, Garber JE, Cramer DW et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000;18:2728-32.
52. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens. Am J Surg Pathol 2001;25:1283-9.
53. Agoff SN, Mendelin JE, Grieco VS, Garcia RL. Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations. Am J Surg Pathol 2002;26:171-8.
54. Colgan TJ, Boerner SL, Murphy J, Cole DE, Narod S, Rosen B. Peritoneal lavage cytology: An assessment of its value during prophylactic oophorectomy. Gynecol Oncol 2002;85:397-403.
55. Gusberg SB, Deligdisch L. Ovarian dysplasia. A study of identical twins. Cancer 1984;54:1-4.
56. Salazar H, Godwin AK, Daly MD et al. Microscopic benign and invasive malignant neoplasms and a cancerprone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996;88:1810-20.
57. Casey MJ, Bewtra C, Hoehne LL, Tatpai AD, Lynch HT, Watson P. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. Gynecol Oncol 2000;78:278-87.
58. Sherman ME, Lee JS, Burks RT, Struewing JP, Kurman RJ, Hartge P. Histopathologic features of ovaries at increased risk for carcinoma. A case-control analysis. Int J Gynecol Pathol 1999;18:151-7.
59. Barakat RR, Federici MG, Saigo PE, Robson ME, Offit K, Boyd J. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimes from BRCA1 heterozygotes. Cancer 2000;89:383-90.
60. Stratton JF, Buckley CH, Lowe D, Ponder BA. Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. J Natl Cancer Inst 1999;91:626-8.
61. Werness BA, Afify AM, Bielat KL, Eltabbakh GH, Piver MS, Paterson JM. Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. Hum Pathol 1999;30:151-7.
62. Auersperg N, Maines-Bandiera SL, Booth JH, Lynch HT, Godwin AK, Hamilton HC. Expression of two mucin antigens in cultured human ovarian surface epithelium: Influence of a family history of ovarian cancer. Am J Obstet Gynecol 1995;173:558-65.
63. Wong AST, Maines-Bandiera SL, Rosen B et al. Constitutive and conditional cadherin expression in cultured human ovarian surface epithelium: Influence of family history of ovarian cancer. Int J Cancer 1999;81:180-8.
64. Kubista M, Rosner M, Kubista E, Bernaschek G, Hengstschager M. Brca1 regulates in vitro differentiation of mammary epithelial cells. Oncogene 2002;21:4747-56.
65. Wong AST, Maines-Bandiera SL, Leung PCK, Auersperg N. Metaplastic changes in cultured human ovarian surface epithelium. In Vitro Cell Dev Biol Anim 1998; 34:668-70.
66. Kruk PA, Godwin AK, Hamilton TC, Auersperg N. Telomeric instability and reduced proliferative potential in ovarian surface epithelial cells from women with a family history of ovarian cancer. Gynecol Oncol 1999;73:229-36.
67. Goldberg JM, Piver SM, Jishi MF, Blumenson L. Age at onset of ovarian cancer in women with a strong family history of ovarian cancer. Gynecol Oncol 1997;66:3-9.
68. Marrs JA, Nelson WJ. Cadherin cell adhesion molecules in differentiation and embryogenesis. Int Rev Cytol 1996; 165:159-205.
69. Birchmeier W. E-cadherin as a tumor (invasion) suppressor gene. Bioessays 1995;17:97-9.
70. Maines-Bandiera SL, Auersperg N. Increased Ecadherin expression in ovarian surface epithelium: An early step in metaplasia and dysplasia? Int J Gynecol Pathol 1997;16:250-5.
71. Darai E, Scoazec JY, Walker-Combrouze F et al. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: A clinicopathologic study of 60 cases. Hum Pathol 1997;28:922-8.
72. Davies BR, Auersperg N, Worsley SD, Ponder BAJ. Transfection of rat ovarian surface epithelium with erbb2/neu induces transformed phenotypes in vitro and the tumorigenic phenotype in vivo. Am J Pathol 1998;152:297-306.
73. Risinger JI, Berchuck A, Kohler MF, Boyd J. Mutations of the E-cadherin gene in human gynecologic cancers. Nature Genet 1994;7:98-102.
74. Liu J, Yang Z, Thompson JA et al. Malignant transformation of human ovarian surface epithelial cells. Proc Am Assoc Cancer Res 2002;43:23 (Abstract).
75. nd Internl Symposium, New York: Pergamon Press, 1980.
76. Adams AT, Auersperg N. Transformation of cultured rat ovarian surface epithelial cells by Kirsten murine sarcoma virus. Cancer Res 1981;41:2063-72.
77. Lail-Trecker MR, Peluso CE, Peluso JJ. Hepatocyte growth factor disrupts cell contact and stimulates an increase in type 3 inositol triphosphate receptor expression, intracellular calcium levels, and apoptosis of rat ovarian surface epithelial cells. Endocrine 2000;12:303-14.
78. Hess S, Gulati R, Peluso JJ. Hepatocyte growth factor induces rat ovarian surface epithelial cell mitosis or apoptosis depending on the presence or absence of an extracellular matrix. Endocrinology 1999;140:2908-16.
79. Hoffman AG, Burghardt RC, Tilley R, Auersperg N. An in vitro model of ovarian epithelial carcinogenesis: Changes in cell-cell communication and adhesion occurring during neoplastic progression. Int J Cancer 1993;54:828-38.
80. Godwin AK, Testa J, Handel L et al. Spontaneous transformation of rat ovarian surface epithelial cells implicates repeated ovulation in ovarian cancer etiology and is associated with clonal cytogenetic changes. J Natl Cancer Inst 1992;84:592-601.
81. Testa J, Getts L, Salazar H et al. Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res 1994;54:2788-84.
82. Nicosia SV, Johnson JH. Surface morphology of ovarian mesothelium (surface epithelium) and of other pelvic and extrapelvic mesothelial sites in the rabbit. Int J Gynecol Pathol 1984;3:249-260.
83. Osterholzer H, Streibel EJ, Nicosia SV. Growth effects of protein hormones on cultured rabbit ovarian surface epithelial cells. Biol Reprod 1985;33:247-58.
84. Pierro E, Nicosia SV, Saunders B, Fultz CB, Nicosia RF, Mancuso S. Influence of growth factors on proliferation and morphogenesis of rabbit ovarian mesothelial cells in vitro. Biol Reprod 1996;54:660-9.
85. Brugarolas J, Jacks T. Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. Nat Med 1997;3:721-2.
86. Deng CX. Tumor formation in Brca1 conditional mutant mice. Environ Mol Mutagen 2002;39:171-7.
87. Xu X, Wagner KU, Larson D et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999;22:37-43.
88. Bennett LM, McAllister KA, Malohrus J et al. Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylbestrol. Cancer Res 2000;60:3461-9.
89. Ludwig T, Fisher P, Murty V, Efstratiadis A. Development of mammary adenocarcinoma by tissue-specific knockout of brca2 in mice. Oncogene 2001;20:3937-48.
90. Selvakumaran M, Bao R, Crijns AP, Connolly DC, Weinstein JK, Hamilton TC. Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element. Cancer Res 2001;61:1291-5.
91. Bao R, Selvakumaran M, Hamilton TC. Targeted gene therapy of ovarian cancer using an ovarian-specific promoter. Gynecol Oncol 2002;84:228-34.
92. Orsulic S, Li Y, Soslow RA et al. Induction of ovarian cancer by defined multipe genetics changes in a mouse model system. Cancer Cell 2002;1:53-62.
93. Rodriguez GC, Nagarsheth NP, Lee KL et al. Progestin-induced apoptosis in the Macaque ovarian epithelium: Differential regulation of transforming growth factor-beta. J Natl Cancer Inst 2002;94:50-60.
94. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002;94:32-8.
95. Parrott JA, Dorasiwamy V, Kim G, Mosher R, Skinner KM. Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol 2001;172:213-22.
96. Parrott JA, Nilsson E, Mosher R et al. Stromal-epithelial interactions in the progression of ovarian cancer: Influence and source of tumor stromal cells. Mol Cell Endocrinol 2001;175:29-39.
97. Fredrickson TN. Ovarian tumors of the hen. Environmental Health Perspectives 1987;73:35-51.
98. Rodriguez GC, Carver D, Anderson K et al. Evaluation of ovarian cancer preventive agents in the chicken. Gynecol Oncol 2001;80:317 (Abstract).
99. MacCalman, CD, Farookhi, R, Blaschuk, OW. Estradiol regulates E-cadherin mRNA levels in the surface epithelium of the mouse ovary. Clin Exp Metastasis 1994;12:276-82.
100. Ryan PL, Valentine AF, Bagnell CA. Expression of epithelial cadherin in the developing and adult pig ovary. Biol Reprod 1996;55:1091-7.
101. Bilderback TR, Lee F, Auersperg N, Rodland KD. Phosphatidylinositol 3-kinase-dependent, MEK-independent proliferation in response to CaR activation. Am J Physiol Cell Physiol 2002;283:C282-8.
102. Shayesteh L, Lu Y, Kuo WL et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
103. Swierenga SH, Auersperg N. Proliferation of human carcinoma cells in calcium-deficient culture medium may depend on autocrine growth factor(s). Exp Cell Biol 1987;55:183-8.
104. Nicosia SV, Saunders PO, Acevedo-Duncan ME, Setrakian S, Degregorio R. Biopathology of ovarian mesothelium. In: Familiari G, Makabe S, Motta PM, eds. Ultrastructure of the Ovary. Boston: Kluwer, 1991;287-310.
105. Nicosia SV, Ku Ni Ni K, Oliveros-Saunders B et al. Ovarian mesothelium (surface epithelium) in normal, pathological and experimental conditions. In: Motta PM, ed, Recent Advances in Microscopy of Cells, Tissues, and Organs. Rome, Antonio Delfino Editore, 1997;509-17
106. Berchuck A, Kohler MF, Boente MP, Rodriguez GC, Whitaker RS, Bast Jr RC. Growth regulation and transformation of ovarian epithelium. Cancer 1993;71:545-51.
107. Wu S, Boyer CM, Whitaker RS et al. Tumor necrosis factor α as an autocrine and paracrine growth factor for ovarian cancer: Monokine induction or tumor cell proliferation and tumor necrosis factor α expression. Cancer Res 1993;53:1939-44.
108. Parrott JA, Mosher R, Kim G, Skinner MK. Autocrine interactions of keratinocyte growth factor, hepatocyte growth factor, and kit-ligand in the regulation of normal ovarian surface epithelial cells. Endocrinology 2000;141:2532-9.
109. Marth C, Zeimet AG, Herold M et al. Different effects of interferons, interleukin-1β and tumor necrosis factor-α in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer 1996;67:826-30.
110. Yee D, Morales FR, Hamilton TC, Von Hoff DD. Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. Cancer Res 1991;51:5107-12.
111. Beck EP, Russo P, Gliozzo B et al. Identification of insulin and insulin-like growth factor I (IGF I) receptors in ovarian cancer tissue. Gynecol Oncol 1994;53:196-201.
112. van Dam PA, Vergote IB, Lowe DG et al. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol 1994;47:914-9.
113. Van Blerkom, Motta PM, eds, The ovary prior to ovulation. In: The Cellular Basis of Mammalian Reproduction. Baltimore: Urban & Scharzenberg, 1979:5-51.
114. Cruet S, Salamanca C, Staedel C, Auersperg N. α-β3/vitronectin expression by normal ovarian surface epithelial cells: Role in cell adhesion and cell proliferation. Gynecol Oncol 1999;75:254-60.
115. Peralta Soler A, Knudsen KA, Jaurand MC et al. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. Hum Pathol 1995;26:1363-9.
116. Kang SK, Choi KC, Cheng KW, Nathwani PS, Auersperg N, Leung PCK. Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium. Endocrinology 2000;141:72-80.
117. Welt CK, Lambert-Messerlian G, Zheng W, Crowley Jr WF, Schneyer AL. Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma. J Clin Endocrinol Metab 1997;82:3720-7.
118. Wu S, Rodabaugh K, Martinez-Maza O et al. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-α. Am J Obstet Gynecol 1992;166:997-1007.
119. Bartlett JM, Landon SP, Scott WN et al. Transforming growth factor-β isoform expression in human ovarian tumors. Eur J Cancer 1997;33:2397-403.
120. Olson TA, Mohanraj D, Carson LF, Ramakrishman S. Vascular permeability factor gene expression in normal and neoplastic ovaries. Cancer Res 1994;54:276-80.
121. Crickard K, Gross JL, Crickard U et al. Basic fibroblast growth factor and receptor expression in human ovarian cancer. Gynecol Oncol 1994;55:277-84.
122. Fang X, Gaudette D, Furui T et al. Lysophospholipid growth factors in the initiation growth progression metastases and management of ovarian cancer. Ann NY Acad Sci 2000;905:188-208.
123. Ziltener HJ, Maines-Bandiera S, Schrader JW, Auersperg N. Secretion of bioactive interleukin-1, interleukin-6, and colony-stimulating factors by human ovarian surface epithelium. Biol Reprod 1993;49:635-41.
124. Cimoli G, Russo P, Billi G, Mariani GL, Rovini E, Venturini M. Human granulocyte-macrophage colony stimulating factor is a growth factor active on human ovarian cancer cells. Jpn J Can Res 1991;82:1196-8.
125. Malik S, Balkwill F. Epithelial ovarian cancer: A cytokine propelled disease? [Editorial] Br J Cancer 1991;64:617-20.
126. Scambia G, Testa U, Panici PB et al. Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer 1994;57:318-23.
127. Balkwill FR. Tumor necrosis factor and cancer. Prog Growth Factor Res 1992;4:121-37.
128. Jacobs I, Bast Jr RC. The CA 125 tumour-associated antigen: A review of the literature. Hum Reprod 1989;4:1-12.
129. Kabawat SE, Bast Jr RC, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC-125. Int J Gynecol Pathol 1983;2:275-85.
130. Zhang S, Zhang HS, Cordon-Carno C, Ragupathi G, Livingston PO. Selection of tumor antigens as targets for immune attack using immunohistochemistry: Protein antigens. Clin Cancer Res 1998;4:2669-76.
131. Mandai M, Konishi I, Kuroda H et al. Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas. Eur J Cancer 1997;33:1501-7.
132. Konishi I, Kuroda H, Mandai M. Review: Gonadotropins and development of ovarian cancer. Oncology 1999;57:45-8.
133. Zheng W, Lu JJ, Luo F et al. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 2000;76:80-8.
134. Lau MK, Mok SC, Ho SM. Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA 1999;96:5722-7.
135. Brandenberger AN, Tee MK, Jaffe RB. Estrogen receptor α (ER-α) and β (ER-β) mRNAs in normal ovary, ovarian serous cystoadenocarcinoma and ovarian cancer cell lines: Down-depletion of ER-β in neoplastic tissues. J Clin Endocrinol Metab 1998;83:1025-8.
136. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774-86.
137. Rao BR, Slotman BJ. Endocrine factors in common epithelial ovarian cancer. Endocr Rev 1991;12:14-26.
138. Clinton GM, Hua W. Estrogen action in human ovarian cancer. Crit Rev Oncol Hematol 1997;25:1-9.
139. Moghul A, Lin L, Beedle A et al. Modulation of c-met proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: Evidence for rapid decay of the 8-kb c-met transcript. Oncogene 1994;9:2045-52.
140. Di Renzo MF, Olivero M, Katsaros D et al. Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer 1994;58:658-62.
141. Owens OJ, Stewart C, Brown I, Leake RE. Epidermal growth factor receptors (EGFR) in human ovarian cancer. Br J Cancer 1991;62:907-10.
142. Dabrow MB, Francesco MR, McBrearty FX, Caradonna S. The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncol 1998;71:29-37.
143. Coppola D, Saunders B, Fu L, Mao W, Nicosia SV. The insulin-like growth factor 1 receptor induces transformation and tumorigenicity of ovarian mesothelial cells and down-regulates their Fas-receptor expression. Cancer Res 1999;59:3264-70.
144. Neufeld F, Tessler S, Gitay-Goren H, Cohen H, Levi BZ. Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 1994;5:89-97.
145. Salmon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu protooncogens in human breast and ovarian cancer. Science 1989;244:710-2.
146. Haldane JS, Hird V, Huges CM, Gullick WJ. c-erbB-2 Oncogene expression in ovarian cancer. J Pathol 1990;162:231-7.